Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | PTAFR | P25105 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587773 | 0.88 | ALDH1A1 (0.50) | HTTSMN1; SMN2GAAALDH1A1HDAC6 | |
| SCHEMBL3608186 | 0.88 | KDM4E (0.54) | LMNAHTTTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL3589932 | 0.87 | LMNA (0.47) | LMNAHTTTSHRSMN1; SMN2GAA | |
| SCHEMBL3595689 | 0.87 | ALDH1A1 (0.51) | LMNAHTTTSHRSMN1; SMN2GAA | |
| SCHEMBL3596889 | 0.85 | HTT (0.66) | LMNAHTTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL3610556 | 0.84 | KDM4E (0.62) | HTTTSHRALDH1A1L3MBTL1 | |
| SCHEMBL3591235 | 0.84 | LMNA (0.39) | LMNAHTTTSHRSMN1; SMN2GAA | |
| SCHEMBL3598189 | 0.81 | TSHR (0.55) | LMNAHTTTSHRGSK3BSMN1; SMN2 | |
| SCHEMBL3599795 | 0.81 | HDAC6 (0.47) | TSHRSMN1; SMN2ALDH1A1HDAC6L3MBTL1 | |
| SCHEMBL3600244 | 0.78 | GAA (0.58) | HTTSMN1; SMN2GAAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807704-B2 | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 | CHEMOCENTRYX, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20070275965-A1 | CXCR4 modulators | CHEMOCENTRYX, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| WO-2007115231-A2 | CXCR4 MODULATORS | CHEMOCENTRYX, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275965-A1 | CXCR4 modulators | CXCL12, CXCR4, CXCR1 | LMNA 4638/4885HTT 1553/4885TSHR 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.